Persistent Asset Partners Ltd Invests $479,000 in Enliven Therapeutics, Inc. $ELVN

Persistent Asset Partners Ltd acquired a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 9,433 shares of the company’s stock, valued at approximately $479,000.

Other hedge funds also recently bought and sold shares of the company. Bank of New York Mellon Corp bought a new position in Enliven Therapeutics in the second quarter valued at about $6,032,000. State of Wyoming bought a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at about $96,000. Tema ETFs LLC grew its stake in shares of Enliven Therapeutics by 41.0% during the 2nd quarter. Tema ETFs LLC now owns 60,694 shares of the company’s stock valued at $3,080,000 after purchasing an additional 17,638 shares during the period. Handelsbanken Fonder AB purchased a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at about $878,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at about $126,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

NASDAQ ELVN opened at $58.82 on Monday. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $62.32. The stock has a market cap of $4.31 billion, a price-to-earnings ratio of -35.22 and a beta of 0.27. The company’s 50 day moving average is $50.90 and its two-hundred day moving average is $40.90.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.67 EPS for the current year.

Insider Activity at Enliven Therapeutics

In related news, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the transaction, the director owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director owned 87,373 shares of the company’s stock, valued at $5,260,728.33. The trade was a 64.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 190,831 shares of company stock worth $10,991,723. 3.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ELVN has been the subject of several recent research reports. Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. The Goldman Sachs Group lifted their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Mizuho boosted their price objective on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. JonesTrading boosted their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, Stifel Nicolaus upped their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Enliven Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $72.67.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.